Sequella receives $2.3M NIH grant for the development of tuberculosis antibiotic drug SQ641
Sequella has received a $2.3 million NIH grant to develop SQ641, a promising new TB drug that demonstrates superior in vitro activity against Mycobacterium tuberculosis. The Phase 2 SBIR grant will fund critical path studies for delivery optimization and IND-related activities.